Literature DB >> 32921207

Growth Differentiation Factor 15 and NT-proBNP as Blood-Based Markers of Vascular Brain Injury and Dementia.

Emer R McGrath1,2, Jayandra J Himali2,3,4,5, Daniel Levy2,6, Sarah C Conner2,4, Charles DeCarli7, Matthew P Pase2,8,9, Toshiharu Ninomiya10, Tomoyuki Ohara10, Paul Courchesne2, Claudia L Satizabal2,5, Ramachandran S Vasan2,4, Alexa S Beiser2,3,4, Sudha Seshadri2,4,5.   

Abstract

Background GDF15 (growth differentiation factor 15) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) may offer promise as biomarkers for cognitive outcomes, including dementia. We determined the association of these biomarkers with cognitive outcomes in a community-based cohort. Methods and Results Plasma GDF15 (n=1603) and NT-proBNP levels (n=1590) (53% women; mean age, 68.7 years) were measured in dementia-free Framingham Offspring cohort participants at examination 7 (1998-2001). Participants were followed up for incident dementia. Secondary outcomes included Alzheimer disease dementia, magnetic resonance imaging structural brain measures, and neurocognitive performance. During a median 11.8-year follow-up, 131 participants developed dementia. On multivariable Cox proportional-hazards analysis, higher circulating GDF15 was associated with an increased risk of incident all-cause and Alzheimer disease dementia (hazard ratio [HR] per SD increment in natural log-transformed biomarker value, 1.54 [95% CI, 1.22-1.95] and 1.37 [95% CI, 1.03-1.81], respectively), whereas higher plasma NT-proBNP was also associated with an increased risk of all-cause dementia (HR, 1.32; 95% CI, 1.05-1.65). Elevated GDF15 was associated with lower total brain and hippocampal volumes, greater white matter hyperintensity volume, and poorer cognitive performance. Elevated NT-proBNP was associated with greater white matter hyperintensity volume and poorer cognitive performance. Addition of both biomarkers to a conventional risk factor model improved dementia risk classification (net reclassification improvement index, 0.25; 95% CI, 0.05-0.45). Conclusions Elevated plasma GDF15 and NT-proBNP were associated with vascular brain injury on magnetic resonance imaging, poorer neurocognitive performance, and increased risk of incident dementia in individuals aged >60 years. Both biomarkers improved dementia risk classification beyond that of traditional clinical risk factors, indicating their potential value in predicting incident dementia.

Entities:  

Keywords:  biomarker; dementia; vascular cognitive impairment

Year:  2020        PMID: 32921207     DOI: 10.1161/JAHA.119.014659

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  6 in total

1.  Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults.

Authors:  Wan-Hsuan Lu; Kelly Virecoulon Giudici; John E Morley; Sophie Guyonnet; Angelo Parini; Geetika Aggarwal; Andrew D Nguyen; Yan Li; Randall J Bateman; Bruno Vellas; Philipe de Souto Barreto
Journal:  Geroscience       Date:  2022-04-20       Impact factor: 7.581

2.  Identification of risk factors for delirium, cognitive decline, and dementia after cardiac surgery (FINDERI-find delirium risk factors): a study protocol of a prospective observational study.

Authors:  Monika Sadlonova; Jonathan Vogelgsang; Claudia Lange; Irina Günther; Adriana Wiesent; Charlotte Eberhard; Julia Ehrentraut; Mareike Kirsch; Niels Hansen; Hermann Esselmann; Charles Timäus; Thomas Asendorf; Benedict Breitling; Mohammed Chebbok; Stephanie Heinemann; Christopher Celano; Ingo Kutschka; Jens Wiltfang; Hassina Baraki; Christine A F von Arnim
Journal:  BMC Cardiovasc Disord       Date:  2022-06-30       Impact factor: 2.174

3.  Growth Differentiation Factor 15 Is Associated With Alzheimer's Disease Risk.

Authors:  Peng-Fei Wu; Xing-Hao Zhang; Ping Zhou; Rui Yin; Xiao-Ting Zhou; Wan Zhang
Journal:  Front Genet       Date:  2021-08-13       Impact factor: 4.599

4.  Cognitive impairment and its association with circulating biomarkers in patients with acute decompensated heart failure.

Authors:  Ying-Chang Tung; Fu-Chih Hsiao; Chia-Pin Lin; Wen-Chuin Hsu; Pao-Hsien Chu
Journal:  J Geriatr Cardiol       Date:  2022-03-28       Impact factor: 3.327

Review 5.  Atrial cardiopathy and cognitive impairment.

Authors:  Sarah J Myers; Amado Jiménez-Ruiz; Luciano A Sposato; Shawn N Whitehead
Journal:  Front Aging Neurosci       Date:  2022-07-22       Impact factor: 5.702

6.  Response of Circulating Inflammatory Markers to Intermittent Hypoxia-Hyperoxia Training in Healthy Elderly People and Patients with Mild Cognitive Impairment.

Authors:  Zoya O Serebrovska; Lei Xi; Lesya V Tumanovska; Angela M Shysh; Sergii V Goncharov; Michael Khetsuriani; Taisia O Kozak; Denis A Pashevin; Victor E Dosenko; Sergii V Virko; Viktor A Kholin; Oksana N Grib; Natalie A Utko; Egor Egorov; Anna O Polischuk; Tetiana V Serebrovska
Journal:  Life (Basel)       Date:  2022-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.